A model of pregnancy-associated malaria for inducing adverse pregnancy outcomes in ICR mouse
CONCLUSIONS: The intraperitoneal injection of 1×106Plasmodium berghei ANKA-infected RBCs could establish a model of pregnancy-associated malaria in ICR mouse.PMID:38158008 | DOI:10.1016/j.exppara.2023.108686 (Source: Experimental Parasitology)
Source: Experimental Parasitology - December 29, 2023 Category: Parasitology Authors: Yingying Zhang Zhiming Liang Haoyu Xing Chuyi Yu Jianming Liang Qin Xu Jianping Song Zhouqing He Source Type: research
A model of pregnancy-associated malaria for inducing adverse pregnancy outcomes in ICR mouse
CONCLUSIONS: The intraperitoneal injection of 1×106Plasmodium berghei ANKA-infected RBCs could establish a model of pregnancy-associated malaria in ICR mouse.PMID:38158008 | DOI:10.1016/j.exppara.2023.108686 (Source: Experimental Parasitology)
Source: Experimental Parasitology - December 29, 2023 Category: Parasitology Authors: Yingying Zhang Zhiming Liang Haoyu Xing Chuyi Yu Jianming Liang Qin Xu Jianping Song Zhouqing He Source Type: research
A model of pregnancy-associated malaria for inducing adverse pregnancy outcomes in ICR mouse
CONCLUSIONS: The intraperitoneal injection of 1×106Plasmodium berghei ANKA-infected RBCs could establish a model of pregnancy-associated malaria in ICR mouse.PMID:38158008 | DOI:10.1016/j.exppara.2023.108686 (Source: Experimental Parasitology)
Source: Experimental Parasitology - December 29, 2023 Category: Parasitology Authors: Yingying Zhang Zhiming Liang Haoyu Xing Chuyi Yu Jianming Liang Qin Xu Jianping Song Zhouqing He Source Type: research
A model of pregnancy-associated malaria for inducing adverse pregnancy outcomes in ICR mouse
CONCLUSIONS: The intraperitoneal injection of 1×106Plasmodium berghei ANKA-infected RBCs could establish a model of pregnancy-associated malaria in ICR mouse.PMID:38158008 | DOI:10.1016/j.exppara.2023.108686 (Source: Experimental Parasitology)
Source: Experimental Parasitology - December 29, 2023 Category: Parasitology Authors: Yingying Zhang Zhiming Liang Haoyu Xing Chuyi Yu Jianming Liang Qin Xu Jianping Song Zhouqing He Source Type: research
In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes
In this study, we evaluated the drug activity of TRZ against amphotericin-B (Amp-B) sensitive and unresponsive Leishmania donovani promastigotes, as well as intracellular amastigotes (drug sensitive). We observed a potent antileishmanial activity of TRZ with significantly low half maximal inhibitory concentrations (IC50) on both the variants of promastigotes (0.61 ± 0.15 μM). These concentrations are comparable to the previously reported IC50 concentration of the current antileishmanial drug (Amp-B) against L. donovani. Light microscopy reveals the perturbations in promastigote morphology upon TRZ treatment. The in vitro...
Source: Experimental Parasitology - December 24, 2023 Category: Parasitology Authors: Vikash Kumar Shobha Kumari Ravi Ranjan Ashish Kumar Dayakar Alti Source Type: research
In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes
In this study, we evaluated the drug activity of TRZ against amphotericin-B (Amp-B) sensitive and unresponsive Leishmania donovani promastigotes, as well as intracellular amastigotes (drug sensitive). We observed a potent antileishmanial activity of TRZ with significantly low half maximal inhibitory concentrations (IC50) on both the variants of promastigotes (0.61 ± 0.15 μM). These concentrations are comparable to the previously reported IC50 concentration of the current antileishmanial drug (Amp-B) against L. donovani. Light microscopy reveals the perturbations in promastigote morphology upon TRZ treatment. The in vitro...
Source: Experimental Parasitology - December 24, 2023 Category: Parasitology Authors: Vikash Kumar Shobha Kumari Ravi Ranjan Ashish Kumar Dayakar Alti Source Type: research
In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes
In this study, we evaluated the drug activity of TRZ against amphotericin-B (Amp-B) sensitive and unresponsive Leishmania donovani promastigotes, as well as intracellular amastigotes (drug sensitive). We observed a potent antileishmanial activity of TRZ with significantly low half maximal inhibitory concentrations (IC50) on both the variants of promastigotes (0.61 ± 0.15 μM). These concentrations are comparable to the previously reported IC50 concentration of the current antileishmanial drug (Amp-B) against L. donovani. Light microscopy reveals the perturbations in promastigote morphology upon TRZ treatment. The in vitro...
Source: Experimental Parasitology - December 24, 2023 Category: Parasitology Authors: Vikash Kumar Shobha Kumari Ravi Ranjan Ashish Kumar Dayakar Alti Source Type: research
In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes
In this study, we evaluated the drug activity of TRZ against amphotericin-B (Amp-B) sensitive and unresponsive Leishmania donovani promastigotes, as well as intracellular amastigotes (drug sensitive). We observed a potent antileishmanial activity of TRZ with significantly low half maximal inhibitory concentrations (IC50) on both the variants of promastigotes (0.61 ± 0.15 μM). These concentrations are comparable to the previously reported IC50 concentration of the current antileishmanial drug (Amp-B) against L. donovani. Light microscopy reveals the perturbations in promastigote morphology upon TRZ treatment. The in vitro...
Source: Experimental Parasitology - December 24, 2023 Category: Parasitology Authors: Vikash Kumar Shobha Kumari Ravi Ranjan Ashish Kumar Dayakar Alti Source Type: research
In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes
In this study, we evaluated the drug activity of TRZ against amphotericin-B (Amp-B) sensitive and unresponsive Leishmania donovani promastigotes, as well as intracellular amastigotes (drug sensitive). We observed a potent antileishmanial activity of TRZ with significantly low half maximal inhibitory concentrations (IC50) on both the variants of promastigotes (0.61 ± 0.15 μM). These concentrations are comparable to the previously reported IC50 concentration of the current antileishmanial drug (Amp-B) against L. donovani. Light microscopy reveals the perturbations in promastigote morphology upon TRZ treatment. The in vitro...
Source: Experimental Parasitology - December 24, 2023 Category: Parasitology Authors: Vikash Kumar Shobha Kumari Ravi Ranjan Ashish Kumar Dayakar Alti Source Type: research
In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes
In this study, we evaluated the drug activity of TRZ against amphotericin-B (Amp-B) sensitive and unresponsive Leishmania donovani promastigotes, as well as intracellular amastigotes (drug sensitive). We observed a potent antileishmanial activity of TRZ with significantly low half maximal inhibitory concentrations (IC50) on both the variants of promastigotes (0.61 ± 0.15 μM). These concentrations are comparable to the previously reported IC50 concentration of the current antileishmanial drug (Amp-B) against L. donovani. Light microscopy reveals the perturbations in promastigote morphology upon TRZ treatment. The in vitro...
Source: Experimental Parasitology - December 24, 2023 Category: Parasitology Authors: Vikash Kumar Shobha Kumari Ravi Ranjan Ashish Kumar Dayakar Alti Source Type: research
In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes
In this study, we evaluated the drug activity of TRZ against amphotericin-B (Amp-B) sensitive and unresponsive Leishmania donovani promastigotes, as well as intracellular amastigotes (drug sensitive). We observed a potent antileishmanial activity of TRZ with significantly low half maximal inhibitory concentrations (IC50) on both the variants of promastigotes (0.61 ± 0.15 μM). These concentrations are comparable to the previously reported IC50 concentration of the current antileishmanial drug (Amp-B) against L. donovani. Light microscopy reveals the perturbations in promastigote morphology upon TRZ treatment. The in vitro...
Source: Experimental Parasitology - December 24, 2023 Category: Parasitology Authors: Vikash Kumar Shobha Kumari Ravi Ranjan Ashish Kumar Dayakar Alti Source Type: research
Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL)
Exp Parasitol. 2023 Dec 17:108687. doi: 10.1016/j.exppara.2023.108687. Online ahead of print.ABSTRACTOBJECTIVES: Post-kala-azar-dermal leishmaniasis (PKDL) is an infectious skin disease that occurs as sequela of visceral leishmaniasis (VL) and causes cutaneous lesions on the face and other exposed body parts. While the first-line drug miltefosine is typically used for 28 days to treat VL, 12 weeks of therapy is required for PKDL, highlighting the need to evaluate the extent of drug penetration at the dermal site of infection. In this proof-of-concept study, we demonstrate the use of a minimally invasive sampling technique ...
Source: Experimental Parasitology - December 19, 2023 Category: Parasitology Authors: Gert-Jan Wijnant Srija Moulik Kingshuk Chatterjee Nilay K Das Ra úl de la Flor Katrien Van Bocxlaer Simon L Croft Mitali Chatterjee Source Type: research
Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL)
Exp Parasitol. 2023 Dec 17:108687. doi: 10.1016/j.exppara.2023.108687. Online ahead of print.ABSTRACTOBJECTIVES: Post-kala-azar-dermal leishmaniasis (PKDL) is an infectious skin disease that occurs as sequela of visceral leishmaniasis (VL) and causes cutaneous lesions on the face and other exposed body parts. While the first-line drug miltefosine is typically used for 28 days to treat VL, 12 weeks of therapy is required for PKDL, highlighting the need to evaluate the extent of drug penetration at the dermal site of infection. In this proof-of-concept study, we demonstrate the use of a minimally invasive sampling technique ...
Source: Experimental Parasitology - December 19, 2023 Category: Parasitology Authors: Gert-Jan Wijnant Srija Moulik Kingshuk Chatterjee Nilay K Das Ra úl de la Flor Katrien Van Bocxlaer Simon L Croft Mitali Chatterjee Source Type: research
Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL)
Exp Parasitol. 2023 Dec 17:108687. doi: 10.1016/j.exppara.2023.108687. Online ahead of print.ABSTRACTOBJECTIVES: Post-kala-azar-dermal leishmaniasis (PKDL) is an infectious skin disease that occurs as sequela of visceral leishmaniasis (VL) and causes cutaneous lesions on the face and other exposed body parts. While the first-line drug miltefosine is typically used for 28 days to treat VL, 12 weeks of therapy is required for PKDL, highlighting the need to evaluate the extent of drug penetration at the dermal site of infection. In this proof-of-concept study, we demonstrate the use of a minimally invasive sampling technique ...
Source: Experimental Parasitology - December 19, 2023 Category: Parasitology Authors: Gert-Jan Wijnant Srija Moulik Kingshuk Chatterjee Nilay K Das Ra úl de la Flor Katrien Van Bocxlaer Simon L Croft Mitali Chatterjee Source Type: research
Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL)
Exp Parasitol. 2023 Dec 17:108687. doi: 10.1016/j.exppara.2023.108687. Online ahead of print.ABSTRACTOBJECTIVES: Post-kala-azar-dermal leishmaniasis (PKDL) is an infectious skin disease that occurs as sequela of visceral leishmaniasis (VL) and causes cutaneous lesions on the face and other exposed body parts. While the first-line drug miltefosine is typically used for 28 days to treat VL, 12 weeks of therapy is required for PKDL, highlighting the need to evaluate the extent of drug penetration at the dermal site of infection. In this proof-of-concept study, we demonstrate the use of a minimally invasive sampling technique ...
Source: Experimental Parasitology - December 19, 2023 Category: Parasitology Authors: Gert-Jan Wijnant Srija Moulik Kingshuk Chatterjee Nilay K Das Ra úl de la Flor Katrien Van Bocxlaer Simon L Croft Mitali Chatterjee Source Type: research
